GLP-1 Medications and FAA Pilot Medical Certification: Aviation Medical Exam Guide
How GLP-1 medications like semaglutide and tirzepatide affect FAA medical certification, BasicMed, and pilot fitness-for-duty requirements.
More on Healthcare Requirements
Key Takeaway
GLP-1 medications are generally compatible with FAA medical certification when used under physician supervision. Report all medications on MedXPress. Stabilize on your dose before flying. Weight loss can actually improve long-term medical certification prospects.
FAA Medical Certification and GLP-1
Pilots must maintain FAA medical certification, which requires disclosure of all medications and medical conditions. The FAA's approach to GLP-1 medications has evolved as these drugs have become mainstream. While not specifically listed as approved or prohibited, they are evaluated based on the individual pilot's response and the conditions being treated. Improving metabolic health with semaglutide or tirzepatide can actually strengthen your long-term medical certification by addressing obesity-related conditions.
Medication Reporting Requirements
All medications must be reported on FAA Form 8500-8 (MedXPress). Include GLP-1 medication name, dose, prescribing reason, start date, and any side effects experienced. Failure to report is a violation regardless of whether the medication would have been approved.
Medical Class Considerations
First Class medical (airline transport), Second Class (commercial), and Third Class (private) all require medication disclosure. BasicMed provides an alternative pathway for private pilots that may simplify the process for GLP-1 users.
Ground Yourself During Titration
When starting GLP-1 medication or increasing dose, consider grounding yourself for 1-2 weeks to assess side effects. The FAA expectation is that pilots should not fly while experiencing any side effects that could impair performance. Nausea and dizziness during titration are the primary concerns.
Steps for Pilots Considering GLP-1
Recommended Approach
- Consult AOPA medical services or aviation medical examiner first
- Start medication during a planned non-flying period
- Document stable use for 30-60 days before resuming flying
- Report accurately on next MedXPress application
Avoid These Mistakes
- Never fail to disclose GLP-1 use on medical forms
- Do not fly on dose increase days when nausea may occur
- Do not assume any medication is automatically approved
- Avoid skipping meals before flights while on GLP-1
Medical Disclaimer: This content is for informational purposes only. Consult an Aviation Medical Examiner (AME) or AOPA medical services before starting GLP-1 medications. FAA policies may change; verify current requirements.
Frequently Asked Questions
Does the FAA allow pilots to use GLP-1 medications?
As of 2026, the FAA reviews GLP-1 medication use on a case-by-case basis for pilot medical certification. Semaglutide and tirzepatide are not on the FAA's Do Not Issue or Do Not Fly lists. Pilots must report all medications on their MedXPress application and may need to provide documentation showing stable use without impairing side effects.
Will GLP-1 medications affect my medical certificate?
GLP-1 medications themselves are generally not disqualifying. However, the conditions they treat (obesity, diabetes) and potential side effects (nausea, dizziness, hypoglycemia) may require AME evaluation. Demonstrating stable use for 30-60 days without significant side effects strengthens your case.
Should I use BasicMed or AME for my medical with GLP-1?
BasicMed may be simpler for pilots using GLP-1 medications, as it involves your personal physician rather than an AME review. However, if you're flying commercially or need a First Class medical, you'll need AME evaluation. Consult an aviation medical examiner familiar with GLP-1 medications.
Can GLP-1 medications cause issues during flight?
The main concerns are nausea and potential hypoglycemia, which could impair pilot performance. Most pilots on stable GLP-1 doses report no issues during flight. Start medication during a non-flying period and ensure you're on a stable dose with no significant side effects before flying.
Start GLP-1 Treatment Today
Compounded semaglutide from $99/mo or tirzepatide from $125/mo.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).